17 Jul 2012 Posted in ABPI statement By Press Office
Stephen Whitehead said:
"The ABPI welcomes the European Commission’s proposal to introduce a new Regulation on Clinical Trials on Medicinal Products for Human Use. This revision gives us a unique opportunity to simplify and standardise the EU environment for conducting clinical research that, if we are ambitious, could enhance the development of medicines, whilst ensuring patient safety is protected.
"The number of clinical trials in Europe and in the UK has been declining in recent years, in part because of the complexity of the EU environment; we now have an opportunity to address the decline, improve patients’ access to the latest clinical research, while encouraging inward investment into the UK."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.